Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 163 of 1,261
  1. US 11787833

    Modified cyclic dinucleoside compounds as sting modulators

    Aligos Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  2. US 11786548

    Trace element compositions, methods of making and use

    American Regent, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  3. US 11787764

    Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  4. US 11786603

    Optimized transglutaminase site-specific antibody conjugation

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  5. US 11786524

    Pharmaceutical compounds

    SENTINEL ONCOLOGY LIMITED · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  6. US 11786635

    Extracellular matrix for treating pelvic floor disorders and skeletal muscle degeneration

    The Regents of the University of California · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  7. US 11786508

    Use of sublingual dexmedetomidine for the treatment of agitation

    BioXcel Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  8. US 11787771

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  9. US 11787869

    Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness

    Dyne Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  10. US 11786602

    ASH1L degraders and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  11. US 11786601

    Pegylated capsule-degrading enzyme for the treatment of anthrax

    The Government of the United States of America, as represented by the Secretary of the Navy · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  12. US 11786598

    Lipid formulations for delivery of therapeutic agents

    ARBUTUS BIOPHARMA CORPORATION · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  13. US 11787800

    BRD9 degraders and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  14. US 11786560

    Immunoisolation device

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  15. US 11786479

    Nucleic acid nanocapsules for drug delivery and targeted gene knockdown

    UNIVERSITY OF CONNECTICUT · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  16. US 11790574

    System and method for carbon dioxide angiographic roadmap imaging

    GE Precision Healthcare LLC · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  17. US 11786486

    Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

    PTC THERAPEUTICS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  18. US 11787867

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  19. US 11788141

    MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells

    Precision for Medicine GmbH · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  20. US 11786554

    Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  21. US 11787840

    Compositions and methods for treating and preventing autoimmune induced cardiac long QT syndrome

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  22. US 11786503

    Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

    Auransa Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  23. US 11786502

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  24. US 11786539

    Aminoglycoside derivatives and uses thereof in treating genetic disorders

    ELOXX PHARMACEUTICALS LTD. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.